诺华铁质积聚新药地拉罗司如何购买？

(Deferasirox) is a new type of iron ion chelator developed by Novartis in Switzerland. By combining with iron ions in the body, it can effectively increase the excretion of iron and reduce the iron content in the body. It can reduce tissue damage and functional damage to multiple organs caused by iron overload.

The drug was approved by the US FDA for marketing in the United States on November 2, 2005. It has been on the market in many European and American countries since 2006. It is the first once-a-day oral iron chelator product and is suitable for children and adult patients over 2 years old with chronic iron overload caused by blood transfusions. In Europe, it is recommended as a first-line drug for thalassemia iron overload patients over 6 years old. The preparation was imported into China on June 30, 2010. At this point, patients can purchase the Novartis new iron-accumulating drug deferasirox they need in China, Europe and the United States and other countries. When purchasing drugs overseas, patients can contact Medical Companion Travel to obtain their specific drug purchasing channels.

Swiss Novartis is an enterprise with a long history and good reputation in the industry. As a leader in the industry, it focuses on improving its R&D level and is the only company in the world that leads the industry in four fields: preventive vaccines, diagnostic reagents, innovative drugs and health care consumer products.

The dose of the new iron accumulation drug produced by Novartis in Switzerland should be determined according to the patient's degree of iron overload and monthly blood transfusion volume: for patients with mild or moderate iron overload who have been transfused with 10 to 20 units of red blood cells and continue to receive regular blood transfusions (receiving blood transfusions of 0.3 to 0.5 mL/kg per day), the recommended dose is 20 mg/d; for patients with severe iron overload (such as serum ferritin >2500g/L) or large amounts of blood transfusions (the dose of blood transfusions received per day) >0.5ml/kg), the recommended dose is 30mg/kg/d to achieve a negative iron balance in the body. Serum ferritin levels should be monitored monthly during treatment, and the dosage can be adjusted by 5 to 10 mg/kg/d every 3 to 6 months according to treatment needs.

Recommended hot articles: No/newsDetail/92201.html